title: [Multidisciplinary management of retinoblastoma: Experience in 37 eyes].
abstract: OBJECTIVE
  To report the results of the multidisciplinary management of patients with retinoblastoma, including survival, enucleation rate, and systemic chemoreduction success.
  
  
  METHODS
  A retrospective study was conducted on 27 patients (37 eyes) diagnosed with retinoblastoma, and treated by a multidisciplinary team in San Juan de Dios Hospital. Demographic information, clinical characterization, survival, local and systemic treatments were included in the analysis. Patients treated with intra-arterial chemotherapy (IAC) were also reviewed.
  
  
  RESULTS
  The study included14 male patients (52%). The median of age at presentation was 8 months (0.16-90). The median follow-up time was 33 ± 21 months. The diagnosis was made in 10 (37%) cases after 15 months old, with a median of 35 months (24-90). 17 (63%) patients had unilateral retinoblastoma, and 10 (37%) bilateral retinoblastoma. Leukocoria, isolated or associated with other signs, was the most frequent reason for referral (63%). Global enucleation rate was 57% (n=21), being the primary treatment in 15 (55%) patients. Enucleation rate in unilateral retinoblastoma was 76.5%, and for bilateral retinoblastoma, it was 60% for one eye and 10% for both. Systemic chemotherapy was prescribed in 17 (63%) patients, with a mean number of cycles of 5.3 ± 2.1. The overall success of chemoreduction and focal therapy in order to avoid external radiotherapy and/or enucleation was 68%. Three patients were treated with IAC as a salvage therapy, controlling the tumor in 2 patients at 6 months of follow-up. These are the first cases reported in Chile. Survival rate was 100%.
  
  
  CONCLUSIONS
  Multidisciplinary management of retinoblastoma led to a survival rate and morbidity comparable with international reports.
authors.affiliation: Departamento de Oftalmología, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: D
authors.initials: D
authors.lastname: Ossandón
authors.affiliation: Departamento de Oftalmología, Hospital San Juan de Dios, Santiago, Chile. Electronic address: mario.zanolli@me.com.
authors.forename: M
authors.initials: M
authors.lastname: Zanolli
authors.affiliation: Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: V
authors.initials: V
authors.lastname: Pérez
authors.affiliation: Departamento de Oftalmología, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: T
authors.initials: T
authors.lastname: Rojas
authors.affiliation: Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: P
authors.initials: P
authors.lastname: Quijarro
authors.affiliation: Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: P
authors.initials: P
authors.lastname: Kabalan
authors.affiliation: Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: D
authors.initials: D
authors.lastname: Alvarez
authors.affiliation: Departamento de Oncología Pediátrica, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: M
authors.initials: M
authors.lastname: Varas
mesh_terms: D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010348:Patient Care Team; D019572:Retinal Neoplasms / Q000628:therapy*; D012175:Retinoblastoma / Q000628:therapy*; D012189:Retrospective Studies
keywords: Chemotherapy; Enucleación; Enucleation; Intra-arterial chemotherapy; Quimioterapia; Quimioterapia intraarterial; Retinoblastoma